Author(s): Harake D, Franco VI, Henkel JM, Miller TL, Lipshultz SE
Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences. Anthracyclines, chemotherapeutic drugs commonly used to treat children with cancer, are known to be cardiotoxic, but the mechanism by which they induce cardiac damage is still not fully understood. A higher cumulative anthracycline dose and a younger age of diagnosis are only a few of the many risk factors that identify the children at increased risk of developing cardiotoxicity. While cardiotoxicity can develop at anytime, starting from treatment initiation and well into adulthood, identifying the best cardioprotective measures to minimize the long-term damage caused by anthracyclines in children is imperative. Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children. Given the serious long-term health consequences of cancer treatments on survivors of childhood cancers, it is essential to investigate new approaches to improving the safety of cancer treatments.
Referred From: https://www.futuremedicine.com/doi/10.2217/fca.12.44
Author(s): Long ZJ, Hu Y, Li XD, He Y, Xiao RZ, et al.
Author(s): Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, et al.
Author(s): Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, et al.
Author(s): Dalen VEC, Raphael MF, Caron HN, Kremer LC
Author(s): Swain SM, Whaley FS, Ewer MS
Author(s): Kobayashi S, Volden P, Timm D, Mao K, Xu X, et al.
Author(s): Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, et al.
Author(s): Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, et al.
Author(s): Cario G, Rhein P, Mitlohner R, Zimmermann M, Bandapalli OR, et al.
Author(s): Aiken MJ, Suhag V, Garcia CA, Acio E, Moreau S, et al.
Author(s): Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE
Author(s): Yeh ET, Bickford CL
Author(s): Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA
Author(s): Vandecruys E, Mondelaers V, De Wolf D, Benoit Y, Suys B
Author(s): Barge-Caballero E, Segovia-Cubero J, Almenar-Bonet L, Gonzalez-Vilchez F, Villa-Arranz A, et al.
Author(s): Schweiger M, Dave H, Lemme F, Cavigelli-Brunner A, Romanchenko O, et al.
Author(s): Kurihara C, Nishimura T, Nawata K, Kinoshita O, Hisagi M, et al.
Author(s): Lipshultz SE, Franco VI, Cochran TR
Author(s): Orgel E, Zung L, Ji L, Finklestein J, Feusner J, et al.
Author(s): Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, et al.
Author(s): Palazzuoli A, Gallotta M, Quatrini I, Nuti R
Author(s): Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, et al.
Author(s): Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, et al.
Author(s): Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, et al.
Author(s): Feuerstein GZ, Ruffolo RR
Author(s): Arozal W, Sari FR, Watanabe K, Arumugam S, Veeraveedu PT, et al.
Author(s): Goldberg JM, Scully RE, Sallan SE, Lipshultz SE
Author(s): Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, et al.